Answers are grounded in this paper and cite their sources.
Fungal infections have increased tremendously in the past few decades [1] contributing to morbidity and mortality. The genus Candida which includes around 200 human pathogenic species [2] is basically a commensal that causes both superficial and systemic infections [3] mainly in immuno compromised hosts like AIDS and cancer patients. Candida albicans, the fourth most common cause of hospital acquired infections, can manifest as a pathogen with the help of germ tube induction and biofilm formation [4]. It is the predominant cause of virtually all types of Candidiasis but other emerging Candida species like C. glabrata, C. krusei, C. Tropicalis and C. parapsilosis are also serious nosocomial threats [5,6]. The conventional drugs available to treat fungal infections are toxic having undesirable side effects and are limited in number largely due to the eukaryotic nature of fungal cells. Till date, it is still difficult to identify unique antifungal targets not shared with human hosts.
No takes yet. Share an insight, caveat, or question.
Nikhat Manzoor (2015) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: